This article is a correction to:
Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
Jingzhen Shi
Yingjie Zhang2,3
Jinzhi Wang
Jianbin Li- 1School of Medicine, Shandong University, Jinan, China
- 2Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
- 3Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
A Corrigendum on
Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
by Shi, J., Zhang, Y., Wang, J., Li, J. and Li, Z. (2020). Front. Oncol. 10:995. doi: 10.3389/fonc.2020.00995
In the original article, there was a mistake in Figure 1 and Table 2 as published. Duplicated panels were contained in Figure 1 due to author error. The authors provided a modified Figure 1 during the review process. The data of the pre-experiment were misplaced in Table 2 and submitted after the proofs due to author error. The corrected Figure 1 and Table 2 appear below.
FIGURE 1
Figure 1. Histological section (H&E) presented that the esophageal patient tissue (P0) was consistent with the series passages (P1, P2, P3, and P4) in the SCID mice (×200).
TABLE 2
Table 2. The detailed data of tumor volume and body weight.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: patient-derived xenograft, esophageal squamous cell carcinoma, anlotinib, chemoradiotherapy, anti-angiogenesis
Citation: Shi J, Zhang Y, Wang J, Li J and Li Z (2020) Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma. Front. Oncol. 10:583499. doi: 10.3389/fonc.2020.583499
Received: 15 July 2020; Accepted: 10 September 2020;
Published: 20 November 2020.
Edited and reviewed by: Massimo Broggini, Mario Negri Pharmacological Research Institute (IRCCS), Italy
Copyright © 2020 Shi, Zhang, Wang, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jianbin Li, lijianbin@msn.com; Zhenxiang Li, lizx0108@163.com